Preview Mode Links will not work in preview mode

 

Welcome to the Empowered Patient Podcast with Karen Jagoda.  This show is a window into the latest innovations in digital health and the changing dynamic between doctors and patients.

Topics on the show include

  • the emergence of personalized medicine and breakthroughs in genomics
  • advances in biopharmaceuticals
  • age related diseases and aging in place
  • using big data from wearables and sensors
  • transparency in the medical marketplace
  • challenges for connected health entrepreneurs

The audience includes researchers, medical professionals, patient advocates, entrepreneurs, patients, caregivers, solution providers, students, journalists, and investors.

Jul 20, 2020

Steven M. Fruchtman, M.D., President and Chief Executive Officer, Onconova Therapeutics discusses Rigosertib, a drug that has the potential to downregulate the RAS pathway, the most commonly mutated gene in cancer. Rigosertib is a proprietary phase 3 small molecule, currently being evaluated in second-line treatment of...


Jul 20, 2020

Steven M. Fruchtman, M.D., President and Chief Executive Officer, Onconova Therapeutics discusses Rigosertib, a drug that has the potential to downregulate the RAS pathway, the most commonly mutated gene in cancer. Rigosertib is a proprietary phase 3 small molecule, currently being evaluated in second-line treatment of...


Jun 25, 2020

Dr. Edith Perez, Chief Medical Officer, Bolt Biotherapeutics discusses an innovative new platform for the treatment of patients with cancer.  The Boltbody platform uses a combination of tumor targeting antibodies and localized stimulation of the immune system, or immune stimulating antibody conjugates, to fight...


Jun 25, 2020

Dr. Edith Perez, Chief Medical Officer, Bolt Biotherapeutics discusses an innovative new platform for the treatment of patients with cancer.  The Boltbody platform uses a combination of tumor targeting antibodies and localized stimulation of the immune system, or immune stimulating antibody conjugates, to fight...


Jun 1, 2020

Dr. Mark Erlander, CEO, Cardiff Oncology identifies the unmet needs of those suffering from metastatic colorectal cancer who have the oncogene KRAS mutation that hyper-drives the tumor growth.  Mark talks about the company's investigational drug, onvansertib that is being evaluated in metastatic colorectal cancer...